Connect with us

Biotechnology

Biotech IPOs Gain Momentum As Five More Companies File

A. Lawrence

Published

on

biotech stocks to buy

Biotech companies have been going public at a pretty impressive pace in the recent months and the trend is all set to continue as five more companies submitted their papers to the Securities and Exchange Commission on Friday last week. Here’s a quick look at each of those five biotech companies.

Akero Therapeutics

The San Francisco based company is one of the few companies which is involved in the development of medicines for treating nonalcoholic steatohepatitis and currently there is no Food and Drugs Administration approved treatment for the condition. The company is targeting a valuation of $86 million in its initial public offering (IPO). The company plans to use the money raised from its IPO for middle stage studies.

Prevail Therapeutics

New York-based Prevail Therapeutics is involved in creating gene therapy medicines for neurodegenerative disorders and its main product is PR001, a treatment for Parkinson’s disease. The company stated in its filing that the drug in question is also being tweaked to treat Gauche disease. The company is looking to get a valuation of $100 million and use the fresh capital to sponsor the next stage of studies with regards to PR001. It has already got FDA approval for clinical trials.

Dermavant Sciences

Dermavent, which is owned almost entirely (99% stake) by Roivant Sciences, is engaged in producing medicines for skin problems, acquired the license from its leading product from Glaxo. Roivant Sciences is engaged in compounds that have been discarded by big pharmaceutical companies and that same strategy seems to be in place at Dermavent.

Dermavent has also started Phase 3 testing for its lead product, that is meant for the treatment of psoriasis and is targeting an IPO valuation of $ 100 million. The money would be used to develop many other drugs that the company wants to bring in to the market.

BridgeBio

As far as the business model is concerned, BridgeBio is similar to Roivant and Dermavent, since it is also engaged in scouring for compounds that have been discarded by big pharma companies. The company is involved in creating experimental treatments meant for genetic problems and the company has a whole range of subsidiaries, who can use BridgeBio’s resources but can also go off on their own if they want. The company has set its target on a valuation of $225 million in its IPO and are going to use the money to facilitate further research at subsidiaries.

Atreca

Last but not the least, Redwood City, California based Atreca has also filed its papers for an IPO, in which the company is seeking a valuation of $100 million. The company has developed its own proprietary technology that helps researchers in finding out antibodies and their targets.

The company claims that its technology has managed to discover as many as 1400 antibodies. The company’s lead product ATRC-101 is an antibody that is meant for treating tumors and Arteca expects to submit its application to the FDA later on in 2019.

Continue Reading
Click to comment

Biotechnology

Biotech Names To Know In November 2019

A. Lawrence

Published

on

best biotechnology stocks to buy sell

Biotech Stocks Have rallied since The End Of September; What’s Next?

Over the years, the biotech sector has become one of the fastest-growing sectors in the stock market and naturally, investors are keen to get hold of stocks that could follow a similar growth trajectory. However, just because a sector is growing does not mean that an investor can bet on any stock and hope to make decent returns.

In order to choose the right stock, he needs to do a lot of personal research and watch the market closely. Here is a look at three biotech stocks that investors should track closely owing to recent developments.

Sernova Corp’s (TSX:SVA) (OTC:SEOVF)

Sernova’s therapeutic approach to regenerative medicine focuses on providing direct cell therapies where the cells, transplanted within an organ-like vascularized implantable device, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

The company’s Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long- term survival and function of therapeutic cells. At the end of October Sernova Corp. (SVA) (SEOVF) detected enduring levels of C-peptide in the bloodstream of a fasting patient in its continuing phase I/II Cell Pouch United States clinical study of type-1 diabetes. This C-peptide is a biomarker of transplanted beta-cell insulin production,

Why is this important? According to Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago, “Along with the preliminary safety and early indicators of efficacy, I am excited that we are observing C-peptide levels in the patient’s bloodstream after recent transplant, not only following stimulation with a meal but also when the patient is fasting. These findings represent progress in clinical outcomes and evidence of enduring islet survival and function within Sernova’s Cell Pouch.”

Read This Full Press Release Here

Genprex (GNPX)

The first one to put in the watch list is that of Genprex Inc (NASDAQ:GNPX). On Tuesday, the company revealed preclinical data from its study of its product TUSC2 immunogene therapy. The product in question is meant for raising the effectiveness of chemotherapy and anti-PD1 in people suffering from metastatic lung cancers.

The data proved to be positive and that has naturally resulted in a rally in the stock. It is a significant development for Genprex and could potentially help the company in cornering an important portion of the gene therapy market. Hence, it is hardly a surprise that the stock has rallied by as much as 60% after hitting a session’s high of $1.09.

 Can Fite Biopharma (CANF)

The other biotech stock that has made a strong move is the Can Fite Biopharma (NYSE:CANF) stock. The biotech company announced this morning that one of its products, which is meant for the treatment of liver diseases and cancer, has been granted a patent as a sexual dysfunction medicine.

The patents have been granted by the relevant authorities in Canada, Israel, and South Korea. In addition to that, the company has also been awarded patents in Japan, China, United States, Australia, and Hong Kong. It is a highly important development for Can-Fite and it was no surprise when the stock rallied this morning. It has rallied by 3% on Tuesday on the back of the news.

top biotech stocks to watch list

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.

Continue Reading

Biotechnology

The Biotech Index Just Hit New Highs; Stocks To Watch

Joe Samuel

Published

on

biotechnology stocks to watch

The Biotech ETF – IBB – Just Made New November Highs, What’s Next?

Investment experts and professional money managers almost always tell people to invest across a range of experts. This is usually in order to generate bigger returns in the long term. One of the sectors that is almost always favored by professionals is the biotech sector and the simple reason behind that is the fact that the sector has managed to grow at an impressive pace.

However, in order to pick stocks, an individual would need to conduct his own research with regard to different companies. Here is a look at three biotech stocks that should be tracked closely due to recent events.

PharmaCyte Biotech (PMCB)

PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

What Happened This Week?

top biotech stocks to buy

This week was important for the company as it hit a milestone never met. The company announced that its partner, Austrianova Singapore, has successfully completed the second and final GMP manufacturing run to produce PharmaCyte’s clinical trial product. The product is now ready for “release testing.”

The data from the “release testing” of both manufacturing runs will be included in an Investigational New Drug application (IND) and submitted to the U.S. Food and Drug Administration to support PharmaCyte’s planned clinical trial in patients with locally advanced, inoperable pancreatic cancer.

“We have cleared what was a major hurdle for us and have completed our most impactful milestone to date. Successfully completing two manufacturing runs is a milestone that has now been met as we progress toward our submission of an IND to the FDA so we can begin our clinical trial in LAPC.”

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner

NovaBay Pharmaceuticals (NBY)

The first biotech stock to consider is that of NovaBay Pharmaceuticals, Inc. (NYSE:NBY). The NovaBay stock has been on a tear this morning owing to an important product announcement from the company. The company issued a press release this morning in which it revealed that its product NovaSight has been launched on Amazon.

The product in question is a mineral supplement and a daily vitamin that is meant for the eyes. After the announcement was made, the stock rose by as much as 26.50% in Monday’s trade and it remains one of the stocks to watch on the market today. The announcement is a significant one and could have far-reaching implications for NovaBay.

REPORT: 1 Biotech Stock is Positioning Itself for Success

BioCryst Pharmaceuticals (BCRX)

Another biotech stock that has been in the middle of a highly impressive rally in recent sessions is that of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). The stock has gained over the course of the past three trading sessions and has generated gains of as much as 28% so far.

In a new development, the company completed a capital raise by offering its equity and managed to raise as much as $55 million. This prompted Bank of America analysts Tazeen Ahmad to upgrade the stock from neutral to buy. The capital raise and the upgrade possibly resulted in the remarkable rally in the BioCryst stock in recent days.

REPORT: 1 Biotech Stock is Positioning Itself for Success

make money with penny stocks biotech

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Biotechnology

3 Biotech Stocks To Watch As Markets Gain Momentum

Joe Samuel

Published

on

biotech stocks to buy

The biotech sector has generated impressive growth over the past decade or so and consequently, many of the biotech stocks in the market have also proven to turn heads. Hence, it is not a surprise that most who look for cutting edge companies focus on the biotech sector.

In order to find the right stocks, an investor needs to do a lot of research and needs to keep a close eye on the latest developments. Here is a quick look at 3 biotech stocks that investors are watching closely this quarter.

PharmaCyte Biotech (PMCB)

PharmaCyte Biotech (PMCB) has developed a drug delivery platform that could be on the verge of a major FDA event. In fact, the news shared on November 18 by the company could be a clear indicator of such an event.

The company announced today that its partner, Austrianova Singapore (Austrianova), has successfully completed the second and final GMP manufacturing run. This was to produce PharmaCyte’s clinical trial product. The product is now ready for “release testing.”

Why Is Release Testing Important For PharmaCyte?

The data from the “release testing” of both manufacturing runs will be included in an Investigational New Drug application (IND) and submitted to the U.S. Food and Drug Administration (FDA). It essentially supports PharmaCyte’s planned clinical trial in patients with locally advanced, inoperable pancreatic cancer.

top biotech stocks to buy

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commented, “Today is a great day at PharmaCyte. We have cleared what was a major hurdle for us and have completed our most impactful milestone to date. Successfully completing two manufacturing runs is a milestone that has now been met as we progress toward our submission of an IND to the FDA so we can begin our clinical trial in LAPC.

Learn more about PharmaCyte Biotech Here

Titan Medical (TMDI)

The first biotech stock that should go into the watch list is that of Titan Medical Inc. (NASDAQ: TMDI). The stock has been on an impressive over the past week or so after the company made a significant announcement.

Titan announced on November 15 that its robotic surgery system has been suspended due to the cash crunch at the company. It stated that it is now looking for options with regards to funding and until then the project will remain suspended.

[Report] 1 Biotech Stock is Positioning Itself for Success.

Investors probably believe that is a positive development since Titan would not be bleeding cash in the middle of a cash crunch and the stock has gone up by as much as 55% after the announcement was made.

Catalyst Pharmaceuticals (CPRX)

The other biotech stock that should be tracked at this point is that of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX). The company announced its financial results for the third quarter on November 14 and there are two important things to keep in mind with regards to the company’s business currently.

biotech stocks to watch now Catalyst Pharmaceuticals (CPRX)

Catalyst announced that its product Firdapse is going to generate $100 million worth of sales for the full year 2019. However, that is well short of analysts’ expectations of $111 million. Additionally, the company’s upper limit for its revenues guidance for 2020 is also short of analysts’ expectations. The higher limit is projected at $155 million but that is $11 million short of analysts’ estimates.

best biotech stocks to watch this month

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com